Evidence map›Paper›PMID 37056385›Full record

ArticleJournal of Cancer2023

Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study.

Izumi Nasu, Masahiro Kondo, Ryuji Uozumi, Shinya Takada, Shuichi Nawata, Hirotoshi Iihara, Yohei Okumura, Masashi Takemoto, Kozo Mino, Tadanori Sasaki and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 11 institutions in 1 country.

Izumi NasuDivision of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Masahiro KondoDepartment of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-cho, Miskuho-ku, Nagoya, Aichi 467-8602, Japan.
Ryuji UozumiDepartment of Industrial Engineering and Economics, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan.
Shinya TakadaDepartment of Pharmacy, National Hospital Organization Hokkaido Cancer Center, 4-2-3-54, Kikusui, Shiroishi-ku, Sapporo 003-0804, Japan.
Shuichi NawataDepartment of Hospital Pharmaceutics, School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Yohei OkumuraDepartment of Pharmacy, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Masashi TakemotoDepartment of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-cho, Miskuho-ku, Nagoya, Aichi 467-8602, Japan.
Kozo MinoDepartment of Pharmacy, National Hospital Organization Hokkaido Cancer Center, 4-2-3-54, Kikusui, Shiroishi-ku, Sapporo 003-0804, Japan.
Tadanori SasakiDepartment of Hospital Pharmaceutics, School of Pharmacy, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Chiemi HiroseDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Tohru AomoriDepartment of Pharmacy, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Rena ShimanoDepartment of Pharmacy, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan.
Ken MaenoDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602, Japan.
Satoshi OizumiDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, 4-2-3-54, Kikusui, Shiroishi-ku, Sapporo 003-0804, Japan.
Sojiro KusumotoRespiratory Medicine and Allergology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Yasushi OhnoDepartment of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Shinnosuke IkemuraDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Daiya TakaiDepartment of Respiratory Medicine, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan.
Azusa HaraDivision of Drug Development and Regulatory Science, Keio University Faculty of Pharmacy, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Hitoshi KawazoeDivision of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Tomonori NakamuraDivision of Pharmaceutical Care Sciences, Keio University Graduate School of Pharmaceutical Sciences, 1-5-30 Shibakoen, Minato-ku, Tokyo 105-8512, Japan.
Keio University · JPShowa University · JPGifu University Hospital · JPKeio University Hospital · JPNagoya City University Hospital · JPSapporo National Hospital · JPToranomon Hospital · JPGifu University · JPNagoya City University · JPNational Hospital Organization Hokkaido Medical Center · JPTokyo Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atezolizumabbaseline medicationsimmune checkpoint inhibitorsnon-small-cell lung cancerpembrolizumabprognostic model

Identifiers

PMID37056385
PMCPMC10088894
OpenAlexW4324009870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.